Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097326 | 0.92 | ADORA2B (0.53) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL16637750 | 0.86 | ADORA2B (0.73) | ADORA2BACACBACACA | |
| SCHEMBL5430644 | 0.86 | ADORA2B (0.48) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL16637949 | 0.85 | ADORA2B (0.62) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL5438969 | 0.83 | ADORA2B (0.47) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL18010252 | 0.83 | ADORA2B (0.40) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL18010250 | 0.83 | ADORA2B (0.40) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL16643810 | 0.83 | MEN1 (0.48) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL16637661 | 0.82 | ADORA2B (0.57) | ADORA2BMEN1KMT2AACACBACACA | |
| SCHEMBL16637157 | 0.82 | ADORA2B (0.71) | ADORA2BADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885MEN1 3162/4885KMT2A 2559/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885MEN1 3162/4885KMT2A 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.